Compare stocks

ANIX vs IPSC

Anixa Biosciences, Inc. and Century Therapeutics, Inc. Common Stock

Compare the businesses

Anixa Biosciences, Inc.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Open ANIX dashboard ↗

Century Therapeutics, Inc. Common Stock

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Open IPSC dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗